Expand MAIA Menu
MAIA MENU

MAIA Latest Press Releases

-- June 10, 2026 --

MAIA Biotechnology Activates and Opens Enrollment at Second U.S. Clinical Site for International Phase 2 THIO-101 Expansion Trial Globe Newswire 9:15 AM

-- June 4, 2026 --

MAIA Biotechnology Reports Strong Enrollment and Dosing Momentum in Pivotal Phase 3 Non-Small Cell Lung Cancer Trial Globe Newswire 9:45 AM

-- June 3, 2026 --

MAIA Biotechnology Receives FDA Clearance to Open U.S. Enrollment in Ongoing Phase 2 THIO-101 Trial Expansion Globe Newswire 9:45 AM

-- June 2, 2026 --

MAIA Biotechnology Announces Open Market Purchases by CEO and Director Globe Newswire 9:45 AM

-- June 1, 2026 --

MAIA Biotechnology Presents Trial in Progress Poster for Pivotal Phase 3 Clinical Trial of Novel Telomere Targeting Agent at 2026 Annual Meeting of American Society of Clinical Oncology Globe Newswire 8:00 AM

-- May 18, 2026 --

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) Globe Newswire 8:00 AM

-- April 16, 2026 --

MAIA Biotechnology Activates First U.S. Site for Ongoing International Phase 2 Expansion Trial of Novel Telomere Targeting Treatment Targeting Advanced Non-Small Cell Lung Cancer Globe Newswire 9:20 AM

-- April 8, 2026 --

MAIA Biotechnology Expects Recent $33 Million Capital Raise to Fully Fund Ongoing Pivotal Phase 3 Trial of Novel Telomere-Targeting Anticancer Therapy Globe Newswire 9:00 AM

-- March 31, 2026 --

MAIA Biotechnology Reports Overall Survival Exceeding Two Years for Eight Patients in Ongoing Phase 2 Clinical Trial in Non-Small Cell Lung Cancer Globe Newswire 9:15 AM

-- March 27, 2026 --

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) Globe Newswire 8:00 AM

-- March 5, 2026 --

Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) Globe Newswire 4:00 PM

-- March 4, 2026 --

MAIA Biotechnology Announces Closing of $30 Million Underwritten Public Offering of Common Stock Globe Newswire 4:00 PM

-- March 2, 2026 --

MAIA Biotechnology Announces Pricing of $30 Million Underwritten Public Offering of Common Stock Globe Newswire 10:45 PM
MAIA Biotechnology Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants Globe Newswire 5:00 PM

-- February 24, 2026 --

MAIA Biotechnology's Phase 3 Momentum Demonstrates Potential Breakthrough Anticancer Opportunity in $50 Billion Immunotherapy Market Globe Newswire 8:45 AM

-- January 20, 2026 --

MAIA Biotechnology Advances Ateganosine Cancer Treatment Program, Outlines Targeted 2026 Clinical Milestones and Growth Momentum Globe Newswire 10:15 AM
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) Globe Newswire 8:00 AM
Market Data Delayed 15 Minutes